Part of New Contract Manufacturing Agreement with SupraNaturals to Secure Additional Production Capacity
SupraNaturals is a leading private label manufacturer in the health and wellness industry
BUZZ BOMB pre-workout:
50mg caffeine for energy and focus.
Boosts performance potential.
Stick packs:
Convenient, no water needed.
Precise caffeine dose
Global Market Insights: Pre-Workout Supplements
Market Size in 2024: $19.6 billion
Projected Market Size by 2030: $27.9 billion
Compound Annual Growth Rate (CAGR): 5.9%
ESTERO, FL / ACCESS Newswire / September 16, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending supplement delivery technology, announced today a strategic initiative to rapidly increase the production capacity of its BUZZ BOMB single dose caffeine pre-workout supplement through a new manufacturing relationship with SupraNaturals, a well-established contract manufacturer of nutritional and dietary supplements. As part of this agreement, Aspire Biopharma announced an initial production order of two million servings (100,000 20-packs) of BUZZ BOMB pre-workout supplement, marking a significant milestone in the Company's expansion efforts.
Aspire's BUZZ BOMB caffeine pre-workout supplement features 50mg of caffeine and is designed to support sustained energy and mental focus, helping athletes and fitness enthusiasts-or anyone needing a lift--maximize their performance potential. Aspire's stick packs are easy to use, do not need to be mixed with water, and contain a precise amount of caffeine.
"Ensuring ample production capacity while maintaining high quality is crucial to our growth," said Kraig Higginson, Interim Chief Executive Officer of Aspire. "Through this manufacturing relationship with SupraNaturals, we expect to achieve the flexibility to scale rapidly, maintain competitive pricing, and meet the high-quality standards our customers expect. Collaborating with an established company like SupraNaturals eliminates upfront capital expenditures and ensures immediate availability to accelerate our sales of BUZZ BOMB."
The flexible capacity allows Aspire to quickly adjust production volumes in response to market demand without delays or significant costs and structured to secure timely and efficient delivery, while maintaining stringent quality control measures. SupraNaturals facility is certified Current Good Manufacturing Practices (cGMP), the main regulatory standard for ensuring quality manufacturing and handling across a variety of industries, including food and beverage; nutritional supplements; health and beauty; and pharmaceuticals.
The global pre-workout supplements market reached a size of $19.6 billion in 2024. By 2030, the market is projected to grow to approximately $27.9 billion, reflecting a compound annual growth rate (CAGR) of 5.9%, highlighting the sector's dynamic expansion.
About SupraNaturals
SupraNaturals is an industry leader in providing the most dynamic options of personal care, food, CBD/hemp and liquid or solid dose nutritional/dietary supplements. With its 300,000+ sq. ft. facility and its swift turn times, SupraNaturals has it all in one facility. In this growing industry, SupraNaturals is dedicated to setting itself apart by delivering a wide variety of innovative products that exceeds the 'normal' customer experience.
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver supplements to the body rapidly and precisely. For more information, please visit www.aspirebiolabs.com
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
Aspire Biopharma Holdings, Inc.
Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/aspire-biopharma-announces-initial-production-order-of-two-million-se-1073930
